CATHERINE D. PERRY, District Judge.
Plaintiffs filed this action in state court on December 12, 2014, alleging personal injuries resulting from use of defendants' drug Xarelto. On July 18, 2017, defendants removed the case to federal court on the basis of diversity jurisdiction, relying on the United States Supreme Court's June 19, 2017 decision in Bristol-Myers Squibb Co. v. Superior Court of California, 137 S.Ct. 1773 (2017). The removal statute, however, precludes removal of diversity cases more than one year after commencement of the action, unless a plaintiff has acted in bad faith to prevent removal. See 28 U.S.C. § 1446(c)(1). Because this case was commenced in state court more than one year before removal and I do not find that plaintiffs acted in bad faith, I will remand it to state court.
Plaintiffs filed their petition in Missouri state court on December 12, 2014.
"A case may not be removed . . . on the basis of jurisdiction conferred by section 1332 more than 1 year after commencement of the action, unless the district court finds that the plaintiff has acted in bad faith in order to prevent a defendant from removing the action." 28 U.S.C. § 1446(c)(1). "In Missouri, a civil action is commenced by filing a petition with the court" and "can only be commenced once," meaning the original filing date, not the filing date of an amended petition, controls. Jackson v. C.R. Bard, Inc., 2017 WL 2021087, at *3 (E.D. Mo. May 12, 2017) (international quotations omitted). "All doubts about federal jurisdiction should be resolved in favor of remand to state court." In re Prempro Products Liab. Litig., 591 F.3d 613, 620 (8th Cir. 2010).
Defendants removed this action on the basis of diversity jurisdiction more than one year after the action was commenced in state court. They cannot do so unless plaintiffs acted in bad faith to prevent them from removing the action. 28 U.S.C. § 1446(c)(1). Defendants argue that plaintiffs acted in bad faith by bringing the claims of non-Missouri plaintiffs in Missouri state court based on a theory of personal jurisdiction that has since been rejected by the Supreme Court in Bristol-Myers. But plaintiffs brought this lawsuit well before the Supreme Court decided Bristol-Myers, and their attempt to secure a favorable forum was permissible within the confines of federal statutes and case law at the time. Bristol-Myers did not create an exception to the application of 28 U.S.C. § 1446(c)(1). See Ingham v. Johnson & Johnson, Case No. 4:17CV1857 SNLJ (E.D. Mo. July 18, 2017). As a result, and because I find no evidence plaintiffs acted in bad faith in order to prevent removal, I must remand this action to state court.
Accordingly,